Study Summary
This trial is testing a new drug for cancer that has not been treated before. It is open to people with cancer that has spread or cannot be removed by surgery.
Eligible Conditions
- Solid Tumors
Treatment Effectiveness
Phase-Based Effectiveness
Phase 2
Study Objectives
6 Primary · 9 Secondary · Reporting Duration: Up to approximately 6 months
From first dose of study drug until disease progression or end of treatment, whichever comes first
Clinical benefit rate (CBR)
Duration of response
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
European Organization for Research and Treatment of Cancer-quality of life quantionnaire-C30 (EORTC-QLQ-C30)
European Quality-5D (EQ-5D)
Number of patients with adverse events and serious adverse events
Objective response rate (ORR)
Overall survival (OS)
Progression free survival (PFS)
Month 6
Time to response
Month 6
Area under the concentration time curve from pre-dose (AUCinf)
Maximum plasma PRL3-zumab concentration (Cmax)
Terminal elimination half life (t½)
Time of Cmax (tmax)
Month 6
Incidence of anti drug antibody (ADA)
Trial Safety
Phase-Based Safety
This is further along than 68% of similar trials
Awards & Highlights
No Placebo Group
All patients enrolled in this trial will receive the new treatment.
Trial Design
1 Treatment Group
PRL3-zumab
1 of 1
Experimental Treatment
55 Total Participants · 1 Treatment Group
Primary Treatment: PRL3-zumab · No Placebo Group · Phase 2
PRL3-zumab
Biological
Experimental Group · 1 Intervention: PRL3-zumab · Intervention Types: BiologicalTrial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to approximately 6 months
Who is running the clinical trial?
ParexelIndustry Sponsor
286 Previous Clinical Trials
93,678 Total Patients Enrolled
Intra-IMMUSG Pte LtdLead Sponsor
Eligibility Criteria
Age 18+ · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:You are expected to live for at least 6 more months.